Raybow Biotech - B (6938.HK): Achieves Third Key Milestone in MASH R&D Collaboration with Boehringer Ingelheim
NewTimeSpace News: Suzhou Raybow Biotech Co., Ltd. (06938.HK) released a voluntary announcement on May 6, 2026, stating that it has reached the third key milestone in its R&D collaboration with Boehringer Ingelheim (BI). The collaboration focuses on developing innovative therapeutic solutions for liver diseases, with a specific focus on Metabolic Dysfunction-Associated Steatohepatitis (MASH).
MASH is a severe and progressive fatty liver disease that can lead to fibrosis, cirrhosis, liver failure, and liver cancer, impacting more than 200 million individuals globally.
Through this collaboration, the Company and BI aim to expand the future potential treatment options pipeline for MASH patients. The achievement of this milestone further strengthens the Company’s position as a strategic partner to global pharmaceutical companies and highlights the commercial potential of its siRNA platform.
As of the date of this announcement, the collaboration remains in the preclinical stage.
- HK Stock Connect Insight | RIBOLIFE-B (06938.HK): Southbound stake rises to 1.93% after Stock Connect inclusion on Sept 7
- RIBOLIFE (06938.HK): EU filing for Phase I trial of SR122
- RIBOLIFE-B (06938.HK): Issues 14,087,085 Consideration Shares to Buy Remaining 49.71% of Ribocure
- RIBOLIFE-B (06938.HK): files EU Phase I trial for obesity drug RBD3133
- RIBOLIFE-B (06938.HK): Included in Hang Seng Composite Index constituents and Stock Connect list effective 7 September